HEADER TRANSFERASE/TRANSFERASE INHIBITOR 29-JAN-16 5HX6 TITLE CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][1,4]OXAZEPIN-4-ONE COMPND MOL_ID: 1; COMPND 2 MOLECULE: RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 1; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 1-294; COMPND 5 SYNONYM: CELL DEATH PROTEIN RIP,RECEPTOR-INTERACTING PROTEIN 1,RIP-1, COMPND 6 SERINE/THREONINE-PROTEIN KINASE RIP; COMPND 7 EC: 2.7.11.1; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: RIPK1, RIP, RIP1; SOURCE 6 EXPRESSION_SYSTEM: BACULOVIRUS EXPRESSION VECTOR PFASTBAC1-HM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 274590 KEYWDS KINASE, INHIBITOR COMPLEX, NON-HINGE BINDING, TRANSFERASE-TRANSFERASE KEYWDS 2 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR N.CAMPOBASSO,P.WARD REVDAT 3 06-MAR-24 5HX6 1 JRNL REMARK REVDAT 2 23-MAR-16 5HX6 1 JRNL REVDAT 1 02-MAR-16 5HX6 0 JRNL AUTH P.A.HARRIS,B.W.KING,D.BANDYOPADHYAY,S.B.BERGER,N.CAMPOBASSO, JRNL AUTH 2 C.A.CAPRIOTTI,J.A.COX,L.DARE,X.DONG,J.N.FINGER,L.C.GRADY, JRNL AUTH 3 S.J.HOFFMAN,J.U.JEONG,J.KANG,V.KASPARCOVA,A.S.LAKDAWALA, JRNL AUTH 4 R.LEHR,D.E.MCNULTY,R.NAGILLA,M.T.OUELLETTE,C.S.PAO, JRNL AUTH 5 A.R.RENDINA,M.C.SCHAEFFER,J.D.SUMMERFIELD,B.A.SWIFT, JRNL AUTH 6 R.D.TOTORITIS,P.WARD,A.ZHANG,D.ZHANG,R.W.MARQUIS,J.BERTIN, JRNL AUTH 7 P.J.GOUGH JRNL TITL DNA-ENCODED LIBRARY SCREENING IDENTIFIES JRNL TITL 2 BENZO[B][1,4]OXAZEPIN-4-ONES AS HIGHLY POTENT AND JRNL TITL 3 MONOSELECTIVE RECEPTOR INTERACTING PROTEIN 1 KINASE JRNL TITL 4 INHIBITORS. JRNL REF J.MED.CHEM. V. 59 2163 2016 JRNL REFN ISSN 0022-2623 JRNL PMID 26854747 JRNL DOI 10.1021/ACS.JMEDCHEM.5B01898 REMARK 2 REMARK 2 RESOLUTION. 2.23 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.23 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 80.18 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 28249 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.202 REMARK 3 R VALUE (WORKING SET) : 0.199 REMARK 3 FREE R VALUE : 0.248 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.050 REMARK 3 FREE R VALUE TEST SET COUNT : 1426 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 14 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.23 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.31 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.07 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2918 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2095 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2769 REMARK 3 BIN R VALUE (WORKING SET) : 0.2073 REMARK 3 BIN FREE R VALUE : 0.2482 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.11 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 149 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4113 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 56 REMARK 3 SOLVENT ATOMS : 29 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 43.53 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 53.63 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 6.60120 REMARK 3 B22 (A**2) : 1.22320 REMARK 3 B33 (A**2) : -7.82440 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.272 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.265 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.209 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.927 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.890 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 8416 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 15270 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1850 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 95 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 1204 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 8416 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 554 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 9024 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.06 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.30 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 16.97 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5HX6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-FEB-16. REMARK 100 THE DEPOSITION ID IS D_1000217887. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-OCT-13 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 21-ID-D REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.078 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28389 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.230 REMARK 200 RESOLUTION RANGE LOW (A) : 131.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 4.800 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHENIX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.84 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.04 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: WELL SOLUTION 26 % PEG 4K, 0.1 M HEPES REMARK 280 PH 7.5; CO-CRYSTALLIZED WITH NEC-4 AND CMPD 8 BACK SOAKED INTO REMARK 280 CRYSTALS AT 5MM CONCENTRATION CRYO WAS TRANSFER 6 % TO 25 % REMARK 280 GLYCEROL ADDED TO WELL SOLUTION, VAPOR DIFFUSION, TEMPERATURE REMARK 280 310K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 21.30000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 65.53000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 50.67500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 65.53000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 21.30000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 50.67500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -8 REMARK 465 ASP A -7 REMARK 465 TYR A -6 REMARK 465 LYS A -5 REMARK 465 ASP A -4 REMARK 465 ASP A -3 REMARK 465 ASP A -2 REMARK 465 ASP A -1 REMARK 465 LYS A 0 REMARK 465 MET A 1 REMARK 465 GLN A 2 REMARK 465 PRO A 3 REMARK 465 ASP A 4 REMARK 465 MET A 5 REMARK 465 SER A 6 REMARK 465 LEU A 7 REMARK 465 ASN A 8 REMARK 465 VAL A 9 REMARK 465 GLY A 26 REMARK 465 GLY A 27 REMARK 465 PHE A 28 REMARK 465 ASN A 170 REMARK 465 GLU A 171 REMARK 465 GLU A 172 REMARK 465 HIS A 173 REMARK 465 ASN A 174 REMARK 465 GLU A 175 REMARK 465 LEU A 176 REMARK 465 ARG A 177 REMARK 465 GLU A 178 REMARK 465 VAL A 179 REMARK 465 ASP A 180 REMARK 465 GLY A 181 REMARK 465 THR A 182 REMARK 465 ALA A 183 REMARK 465 LYS A 184 REMARK 465 LYS A 185 REMARK 465 ASN A 186 REMARK 465 GLY A 187 REMARK 465 GLU A 229 REMARK 465 ASN A 230 REMARK 465 ALA A 231 REMARK 465 ILE A 232 REMARK 465 ALA A 233 REMARK 465 MET B -8 REMARK 465 ASP B -7 REMARK 465 TYR B -6 REMARK 465 LYS B -5 REMARK 465 ASP B -4 REMARK 465 ASP B -3 REMARK 465 ASP B -2 REMARK 465 ASP B -1 REMARK 465 LYS B 0 REMARK 465 MET B 1 REMARK 465 GLN B 2 REMARK 465 PRO B 3 REMARK 465 ASP B 4 REMARK 465 MET B 5 REMARK 465 SER B 6 REMARK 465 LEU B 7 REMARK 465 ASN B 8 REMARK 465 ALA B 21 REMARK 465 GLU B 22 REMARK 465 LEU B 23 REMARK 465 ASP B 24 REMARK 465 SER B 25 REMARK 465 GLY B 26 REMARK 465 GLY B 27 REMARK 465 PHE B 28 REMARK 465 GLY B 29 REMARK 465 LYS B 30 REMARK 465 ARG B 177 REMARK 465 GLU B 178 REMARK 465 VAL B 179 REMARK 465 ASP B 180 REMARK 465 GLY B 181 REMARK 465 THR B 182 REMARK 465 ALA B 183 REMARK 465 LYS B 184 REMARK 465 LYS B 185 REMARK 465 ASN B 186 REMARK 465 GLY B 187 REMARK 465 GLY B 188 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ILE A 10 CG1 CG2 CD1 REMARK 470 LYS A 11 CG CD CE NZ REMARK 470 GLU A 19 CG CD OE1 OE2 REMARK 470 LEU A 23 CG CD1 CD2 REMARK 470 ASP A 24 CG OD1 OD2 REMARK 470 SER A 25 OG REMARK 470 LYS A 30 CG CD CE NZ REMARK 470 GLN A 39 CG CD OE1 NE2 REMARK 470 GLU A 55 CG CD OE1 OE2 REMARK 470 GLU A 107 CG CD OE1 OE2 REMARK 470 MET A 108 CG SD CE REMARK 470 LYS A 167 CG CD CE NZ REMARK 470 GLU A 234 CG CD OE1 OE2 REMARK 470 GLN A 235 CG CD OE1 NE2 REMARK 470 GLN A 236 CG CD OE1 NE2 REMARK 470 VAL B 31 CG1 CG2 REMARK 470 GLN B 39 CG CD OE1 NE2 REMARK 470 GLU B 58 CG CD OE1 OE2 REMARK 470 GLU B 107 CG CD OE1 OE2 REMARK 470 MET B 108 CG SD CE REMARK 470 GLU B 172 CG CD OE1 OE2 REMARK 470 HIS B 173 CG ND1 CD2 CE1 NE2 REMARK 470 ASN B 199 CG OD1 ND2 REMARK 470 ASP B 200 CG OD1 OD2 REMARK 470 LYS B 204 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 21 117.06 -164.63 REMARK 500 LYS A 137 -26.98 72.33 REMARK 500 ASP A 200 70.92 -162.86 REMARK 500 ASP B 16 -24.23 -173.27 REMARK 500 GLU B 19 157.32 -48.33 REMARK 500 THR B 38 -39.82 -134.15 REMARK 500 LYS B 87 103.49 -163.91 REMARK 500 LYS B 137 -13.27 75.95 REMARK 500 ASP B 138 45.68 -144.06 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 65U A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 65U B 301 DBREF 5HX6 A 1 294 UNP Q13546 RIPK1_HUMAN 1 294 DBREF 5HX6 B 1 294 UNP Q13546 RIPK1_HUMAN 1 294 SEQADV 5HX6 MET A -8 UNP Q13546 INITIATING METHIONINE SEQADV 5HX6 ASP A -7 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 TYR A -6 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 LYS A -5 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP A -4 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP A -3 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP A -2 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP A -1 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 LYS A 0 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ALA A 34 UNP Q13546 CYS 34 ENGINEERED MUTATION SEQADV 5HX6 ALA A 127 UNP Q13546 CYS 127 ENGINEERED MUTATION SEQADV 5HX6 ALA A 233 UNP Q13546 CYS 233 ENGINEERED MUTATION SEQADV 5HX6 ALA A 240 UNP Q13546 CYS 240 ENGINEERED MUTATION SEQADV 5HX6 MET B -8 UNP Q13546 INITIATING METHIONINE SEQADV 5HX6 ASP B -7 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 TYR B -6 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 LYS B -5 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP B -4 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP B -3 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP B -2 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ASP B -1 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 LYS B 0 UNP Q13546 EXPRESSION TAG SEQADV 5HX6 ALA B 34 UNP Q13546 CYS 34 ENGINEERED MUTATION SEQADV 5HX6 ALA B 127 UNP Q13546 CYS 127 ENGINEERED MUTATION SEQADV 5HX6 ALA B 233 UNP Q13546 CYS 233 ENGINEERED MUTATION SEQADV 5HX6 ALA B 240 UNP Q13546 CYS 240 ENGINEERED MUTATION SEQRES 1 A 303 MET ASP TYR LYS ASP ASP ASP ASP LYS MET GLN PRO ASP SEQRES 2 A 303 MET SER LEU ASN VAL ILE LYS MET LYS SER SER ASP PHE SEQRES 3 A 303 LEU GLU SER ALA GLU LEU ASP SER GLY GLY PHE GLY LYS SEQRES 4 A 303 VAL SER LEU ALA PHE HIS ARG THR GLN GLY LEU MET ILE SEQRES 5 A 303 MET LYS THR VAL TYR LYS GLY PRO ASN CYS ILE GLU HIS SEQRES 6 A 303 ASN GLU ALA LEU LEU GLU GLU ALA LYS MET MET ASN ARG SEQRES 7 A 303 LEU ARG HIS SER ARG VAL VAL LYS LEU LEU GLY VAL ILE SEQRES 8 A 303 ILE GLU GLU GLY LYS TYR SER LEU VAL MET GLU TYR MET SEQRES 9 A 303 GLU LYS GLY ASN LEU MET HIS VAL LEU LYS ALA GLU MET SEQRES 10 A 303 SER THR PRO LEU SER VAL LYS GLY ARG ILE ILE LEU GLU SEQRES 11 A 303 ILE ILE GLU GLY MET ALA TYR LEU HIS GLY LYS GLY VAL SEQRES 12 A 303 ILE HIS LYS ASP LEU LYS PRO GLU ASN ILE LEU VAL ASP SEQRES 13 A 303 ASN ASP PHE HIS ILE LYS ILE ALA ASP LEU GLY LEU ALA SEQRES 14 A 303 SER PHE LYS MET TRP SER LYS LEU ASN ASN GLU GLU HIS SEQRES 15 A 303 ASN GLU LEU ARG GLU VAL ASP GLY THR ALA LYS LYS ASN SEQRES 16 A 303 GLY GLY THR LEU TYR TYR MET ALA PRO GLU HIS LEU ASN SEQRES 17 A 303 ASP VAL ASN ALA LYS PRO THR GLU LYS SER ASP VAL TYR SEQRES 18 A 303 SER PHE ALA VAL VAL LEU TRP ALA ILE PHE ALA ASN LYS SEQRES 19 A 303 GLU PRO TYR GLU ASN ALA ILE ALA GLU GLN GLN LEU ILE SEQRES 20 A 303 MET ALA ILE LYS SER GLY ASN ARG PRO ASP VAL ASP ASP SEQRES 21 A 303 ILE THR GLU TYR CYS PRO ARG GLU ILE ILE SER LEU MET SEQRES 22 A 303 LYS LEU CYS TRP GLU ALA ASN PRO GLU ALA ARG PRO THR SEQRES 23 A 303 PHE PRO GLY ILE GLU GLU LYS PHE ARG PRO PHE TYR LEU SEQRES 24 A 303 SER GLN LEU GLU SEQRES 1 B 303 MET ASP TYR LYS ASP ASP ASP ASP LYS MET GLN PRO ASP SEQRES 2 B 303 MET SER LEU ASN VAL ILE LYS MET LYS SER SER ASP PHE SEQRES 3 B 303 LEU GLU SER ALA GLU LEU ASP SER GLY GLY PHE GLY LYS SEQRES 4 B 303 VAL SER LEU ALA PHE HIS ARG THR GLN GLY LEU MET ILE SEQRES 5 B 303 MET LYS THR VAL TYR LYS GLY PRO ASN CYS ILE GLU HIS SEQRES 6 B 303 ASN GLU ALA LEU LEU GLU GLU ALA LYS MET MET ASN ARG SEQRES 7 B 303 LEU ARG HIS SER ARG VAL VAL LYS LEU LEU GLY VAL ILE SEQRES 8 B 303 ILE GLU GLU GLY LYS TYR SER LEU VAL MET GLU TYR MET SEQRES 9 B 303 GLU LYS GLY ASN LEU MET HIS VAL LEU LYS ALA GLU MET SEQRES 10 B 303 SER THR PRO LEU SER VAL LYS GLY ARG ILE ILE LEU GLU SEQRES 11 B 303 ILE ILE GLU GLY MET ALA TYR LEU HIS GLY LYS GLY VAL SEQRES 12 B 303 ILE HIS LYS ASP LEU LYS PRO GLU ASN ILE LEU VAL ASP SEQRES 13 B 303 ASN ASP PHE HIS ILE LYS ILE ALA ASP LEU GLY LEU ALA SEQRES 14 B 303 SER PHE LYS MET TRP SER LYS LEU ASN ASN GLU GLU HIS SEQRES 15 B 303 ASN GLU LEU ARG GLU VAL ASP GLY THR ALA LYS LYS ASN SEQRES 16 B 303 GLY GLY THR LEU TYR TYR MET ALA PRO GLU HIS LEU ASN SEQRES 17 B 303 ASP VAL ASN ALA LYS PRO THR GLU LYS SER ASP VAL TYR SEQRES 18 B 303 SER PHE ALA VAL VAL LEU TRP ALA ILE PHE ALA ASN LYS SEQRES 19 B 303 GLU PRO TYR GLU ASN ALA ILE ALA GLU GLN GLN LEU ILE SEQRES 20 B 303 MET ALA ILE LYS SER GLY ASN ARG PRO ASP VAL ASP ASP SEQRES 21 B 303 ILE THR GLU TYR CYS PRO ARG GLU ILE ILE SER LEU MET SEQRES 22 B 303 LYS LEU CYS TRP GLU ALA ASN PRO GLU ALA ARG PRO THR SEQRES 23 B 303 PHE PRO GLY ILE GLU GLU LYS PHE ARG PRO PHE TYR LEU SEQRES 24 B 303 SER GLN LEU GLU HET 65U A 301 47 HET 65U B 301 47 HETNAM 65U 5-BENZYL-N-[(3S)-5-METHYL-4-OXO-2,3,4,5-TETRAHYDRO-1,5- HETNAM 2 65U BENZOXAZEPIN-3-YL]-1,2-OXAZOLE-3-CARBOXAMIDE FORMUL 3 65U 2(C21 H19 N3 O4) FORMUL 5 HOH *29(H2 O) HELIX 1 AA1 LYS A 13 SER A 15 5 3 HELIX 2 AA2 HIS A 56 ARG A 69 1 14 HELIX 3 AA3 ASN A 99 LYS A 105 1 7 HELIX 4 AA4 PRO A 111 LYS A 132 1 22 HELIX 5 AA5 LYS A 140 GLU A 142 5 3 HELIX 6 AA6 PHE A 162 LEU A 168 1 7 HELIX 7 AA7 ALA A 194 LEU A 198 5 5 HELIX 8 AA8 THR A 206 ASN A 224 1 19 HELIX 9 AA9 GLN A 235 SER A 243 1 9 HELIX 10 AB1 ASP A 248 ILE A 252 5 5 HELIX 11 AB2 PRO A 257 TRP A 268 1 12 HELIX 12 AB3 ASN A 271 ARG A 275 5 5 HELIX 13 AB4 THR A 277 LEU A 293 1 17 HELIX 14 AB5 CYS B 53 ARG B 69 1 17 HELIX 15 AB6 LEU B 100 ALA B 106 1 7 HELIX 16 AB7 PRO B 111 LYS B 132 1 22 HELIX 17 AB8 LYS B 140 GLU B 142 5 3 HELIX 18 AB9 PHE B 162 ASN B 169 1 8 HELIX 19 AC1 THR B 189 MET B 193 5 5 HELIX 20 AC2 ALA B 194 LEU B 198 5 5 HELIX 21 AC3 THR B 206 ASN B 224 1 19 HELIX 22 AC4 ALA B 233 SER B 243 1 11 HELIX 23 AC5 ASP B 248 ILE B 252 5 5 HELIX 24 AC6 PRO B 257 TRP B 268 1 12 HELIX 25 AC7 ASN B 271 ARG B 275 5 5 HELIX 26 AC8 THR B 277 LEU B 293 1 17 SHEET 1 AA1 6 LYS A 11 MET A 12 0 SHEET 2 AA1 6 LEU A 78 ILE A 83 1 O VAL A 81 N MET A 12 SHEET 3 AA1 6 LYS A 87 GLU A 93 -1 O VAL A 91 N GLY A 80 SHEET 4 AA1 6 GLY A 40 LYS A 49 -1 N VAL A 47 O TYR A 88 SHEET 5 AA1 6 VAL A 31 HIS A 36 -1 N HIS A 36 O GLY A 40 SHEET 6 AA1 6 PHE A 17 GLU A 19 -1 N GLU A 19 O PHE A 35 SHEET 1 AA2 6 LYS A 11 MET A 12 0 SHEET 2 AA2 6 LEU A 78 ILE A 83 1 O VAL A 81 N MET A 12 SHEET 3 AA2 6 LYS A 87 GLU A 93 -1 O VAL A 91 N GLY A 80 SHEET 4 AA2 6 GLY A 40 LYS A 49 -1 N VAL A 47 O TYR A 88 SHEET 5 AA2 6 VAL A 31 HIS A 36 -1 N HIS A 36 O GLY A 40 SHEET 6 AA2 6 GLU A 22 LEU A 23 -1 N LEU A 23 O VAL A 31 SHEET 1 AA3 2 ILE A 144 VAL A 146 0 SHEET 2 AA3 2 ILE A 152 ILE A 154 -1 O LYS A 153 N LEU A 145 SHEET 1 AA4 4 SER B 32 HIS B 36 0 SHEET 2 AA4 4 GLY B 40 TYR B 48 -1 O GLY B 40 N HIS B 36 SHEET 3 AA4 4 LYS B 87 GLU B 93 -1 O TYR B 88 N TYR B 48 SHEET 4 AA4 4 LEU B 78 GLU B 84 -1 N GLU B 84 O LYS B 87 SHEET 1 AA5 3 GLY B 98 ASN B 99 0 SHEET 2 AA5 3 ILE B 144 VAL B 146 -1 O VAL B 146 N GLY B 98 SHEET 3 AA5 3 ILE B 152 ILE B 154 -1 O LYS B 153 N LEU B 145 SITE 1 AC1 11 VAL A 31 LYS A 45 LEU A 70 VAL A 76 SITE 2 AC1 11 LEU A 78 LEU A 90 MET A 92 HIS A 136 SITE 3 AC1 11 ILE A 154 ASP A 156 LEU A 157 SITE 1 AC2 14 ILE B 43 LYS B 45 LEU B 70 VAL B 76 SITE 2 AC2 14 LEU B 78 LEU B 90 MET B 92 HIS B 136 SITE 3 AC2 14 ILE B 154 ALA B 155 ASP B 156 LEU B 157 SITE 4 AC2 14 LEU B 159 SER B 161 CRYST1 42.600 101.350 131.060 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023474 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009867 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007630 0.00000